

## PIETRO MERLI

### Curriculum Vitae

Place Rome, Italy  
Date February 10<sup>th</sup>, 2021

#### General Information

Full Name	Pietro Merli
Date of Birth	17/09/1982
Citizenship	Italian
E-mail	<a href="mailto:Pietro.merli@opbg.net">Pietro.merli@opbg.net</a>
Spoken Languages	Italian, English

#### Education

Type	Year	Institution	Notes (Degree, Experience,...)
Post-graduate studies	2015	Sapienza University of Rome	Master degree in Pediatric Intensive Care; 50/50 cum laude
Specialty	2013	University of Pavia	Pediatrics; 50/50 cum Laude
University graduation	2007	University of Pavia	Medicine and Surgery; 110/110 cum laude

#### Qualifications

Qualification	Since 2015	PALS	PALS (Pediatric Advanced Life Support) performer
Qualification	Since 2013	PBLS	PBLS (Pediatric Basic Life Support) performer

#### Appointments

Start	End	Institution	Position
April 2018	Present	Bambino Gesù Children's Hospital, Rome, Italy	Staff Physician - High specialization in hematopoietic stem cell transplantation in malignant blood disorders
April 2015	March 2018	Bambino Gesù Children's Hospital, Rome, Italy	Staff Physician
May 2013	March 2015	Bambino Gesù Children's Hospital, Rome, Italy	Fellowship

#### Society memberships, Awards and Honors

Year	Title
Since	Member of Italian Society of Pediatrics (SIP)

2013	
Since 2020	Member of The Italian Association of Pediatric Haematology and Oncology (AIEOP)
2016	Best Young Abstract Award related to haploidentical transplantation at EBMT 2016
2019	Best Oral presentation; AIEOP Annual Meeting

### Working group

Since 2015	Member of the Italian working group on non-lymphoblastic acute leukemias (AIEOP)
Since 2016	Mount Sinai Acute Graft-versus-Host Disease International Consortium (MAGIC)
Since 2017	Molecular Acute Myeloid Leukemia Monitoring group of the AML-BFM study
Since 2017	Pediatric Disease Working Party (PDWP) dell'European Society for Blood and Marrow Transplantation (EBMT)

### Research Activities

Keywords	Brief Description
Hematopoietic Stem Cell Transplantation	<p>High specialization in hematopoietic stem cell transplantation in malignant blood disorders. Clinical experience in diagnosis and treatment (in particular hematopoietic stem cell transplantation) of pediatric onco-hematologic patients, with particular interest in acute leukemias and non-malignant diseases (immunodeficiencies, red blood cell disorders, inherited bone marrow failure syndromes). Experience in innovative treatments: investigator in a number of either academic or sponsored clinical trials (from phase I to phase III), including trials on immunotherapy, gene therapy and genome editing.</p> <p>Other translational research interests include: conditioning regimen and graft manipulation strategies in HSCT; characterization of graft failure and Graft-versus-Host Disease after HSCT; role of microbiota (and possible interventions, such as fecal microbiota transplantation) in the HSCT setting.</p>
Cell Therapies	
Gene Therapy	
Graft Failure	
Hemophagocytic Lymphohistiocytosis	
Fecal Microbiota Transplantation	

### Principal Investigator

- ATA129-RS002 “A Retrospective Study of Treatment Outcomes in Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorder after Hematopoietic Cell Transplant or Solid Organ Transplant who have Failed Rituximab or Rituximab Plus Chemotherapy”. Bambino Gesù Children’s Hospital, 2020
- NI-0501-13 “A clinical study to investigate Interferon gamma (IFN $\gamma$ ) signature in patients post HSCT and in patients with impaired HSC proliferation pre-transplant”. Bambino Gesù Children’s Hospital, 2021

### Sub Investigator

- Sub-investigator for "A Pilot, Open-label, Single Arm, Multicentre Study to Explore Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Multiple Administrations of NI-0501, an Anti-interferon Gamma (Anti-IFN $\gamma$ ) Monoclonal Antibody, in Paediatric Patients with Primary

Haemophagocytic Lymphohistiocytosis (HLH)" PROTOCOL NI-0501-04. EudraCT number: 2012-003632-23. Sponsor: Novimmune. 2013

- Sub-investigator for "Phase I/II study of CaspaCide T cells from an HLA-partially matched family donor after negative selection of TCR  $\alpha\beta$ + T cells in pediatric patients affected by hematological disorders" Protocol BP-004. EudraCT Number: 2014-000584-41. Sponsor: Bellicum Pharmaceuticals. 2014
- Sub-investigator for "Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia. ALL SCTped 2012 FORUM". EudraCT number: 2012-003032-22. Sponsor: St. Anna Kinderkrebsforschung. 2015
- Sub-investigator for "Study protocol for acute myeloid leukemia in children and adolescent". Protocol: LAM 2013/01. EudraCT number: 2014-000652-28. Sponsor: AIEOP. 2015
- Sub-investigator for "Clinical phase II study to describe the safety and efficacy of Treosulfan-based conditioning therapy prior to allogeneic stem cell transplantation in paediatric patients with haematological malignancies". Protocol MC-FludT.17/M. EudraCT number: 2013-003604-39. Sponsor: Medac GmbH. 2015
- Sub-investigator for "Single-Arm Study to Assess the Efficacy of UVADEX® (methoxsalen) Sterile Solution in Conjunction with the THERAKOS® CELLEX® Photopheresis System in Pediatric Patients with Steroid-Refractory Acute Graft Versus Host Disease (aGvHD)". Protocolo TKS-2014-001. EudraCT number: 2014-004806-14. Sponsor: Therakos. 2016
- Sub-investigator for "A Phase 3 Single Arm Study Evaluating the Efficacy and Safety of Gene Therapy in Subjects with Transfusion-dependent  $\beta$ -Thalassemia, who do not have  $\beta^0/\beta^0$  Genotype, by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with a Lentiviral  $\beta$ A-T87Q-Globin Vector in Subjects  $\geq 12$  and  $\leq 50$  Years of Age". Protocol HGB-207. EudraCT number: 2015-004122-33. Sponsor: BlueBird Bio. 2016
- Sub-investigator for "Mount Sinai Acute Graft-versus-Host Disease International Consortium (MAGIC): A Database and Biorepository". Protocol: MAGIC. Sponsor: Icahn School of Medicine at Mount Sinai. 2016
- Sub-investigator for "A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant". Protocol: 15-007. EudraCT number: 2016-002004-10. Sponsor: Jazz Pharmaceuticals. 2016
- Sub-investigator for "A Phase I Study of Safety, Pharmacokinetics and Efficacy of Donor BPX-501 Cells and AP1903 Infusion for Children with Recurrent or Minimal Residual Disease Hematologic Malignancies After Allogeneic Transplant". Protocol: BP-I-008. EudraCT number: 2015-005176-17. Sponsor: Bellicum Pharmaceuticals. 2016
- Sub-investigator for "A phase III randomized open-label multi-center study of ruxolitinib versus best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogeneic stem cell transplantation". Protocol CINC424C2301. EudraCT number: 2016-002584-33. Sponsor: Novartis. 2016
- Sub-investigator for "Follow-up of phase I/II study of CaspaCide T cells from an HLA-partially matched family donor after negative selection of TCR  $\alpha\beta$ + T cells in pediatric patients affected by hematological disorders". Protocol: BP-404. EudraCT number: 2016-003226-16. Sponsor: Bellicum Pharmaceuticals. 2017
- Sub-investigator for "A Phase 3 Single Arm Study Evaluating the Efficacy and Safety of Gene Therapy in Subjects with Transfusion-dependent  $\beta$  Thalassemia, who have a  $\beta^0/\beta^0$  Genotype, by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with a Lentiviral  $\beta$ A T87Q Globin Vector in Subjects  $\leq 50$  Years of Age". Protocol HGB-212. EudraCT number: 2016-003611-35. Sponsor: BlueBird Bio. 2017
- Sub-investigator for "A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination With Corticosteroids versus Placebo in Combination With Corticosteroids in Subjects with New Onset Chronic Graft Versus Host Disease (cGVHD)". Protocol PCYC-1140-IM. EudraCT number: 2016-003286-26. Sponsor: Pharmacyclics. 2017
- Sub-investigator for "Phase I/II study of anti-CD19 Chimeric Antigen Receptor-Expressing T cells in pediatric patients affected by relapsed/refractory CD19+ Acute Lymphoblastic Leukemia and Non

- Hodgkin Lymphoma". Protocol CD19-CAR01. EudraCT number: 2017-002088-16. Sponsor: Ospedale Pediatrico Bambino Gesù. 2017
- Sub-investigator for "Phase I/II study of anti-GD2 Chimeric Antigen Receptor-Expressing T cells in pediatric patients affected by High Risk and/or relapsed/refractory Neuroblastoma". Protocol GD2CAR01. EudraCT number: 2017-002475-26. Sponsor: Ospedale Pediatrico Bambino Gesù. 2017
  - Sub-investigator for "Treatment of severe steroid-refractory acute GvHD with mesenchymal stromal cells. A phase III, randomized double-blind multi-center HOVON study". Protocol: HOVON 113. EudraCT number: 2012-004915-30. Sponsor: HOVON Foundation. 2018
  - Sub-investigator for "A phase II trial of tisagenlecleucel in first-line high-risk (HR) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who are minimal residual disease (MRD) positive at the end of consolidation (EOC) therapy". Protocol: CCTL019G2201J. EudraCT number: 2017-002116-14. Sponsor: Novartis. 2019
  - Sub-investigator for " A Phase II, single arm, multicenter open label trial to determine the safety and efficacy of tisagenlecleucel in pediatric patients with relapsed or refractory mature B-cell non-Hodgkin lymphoma (NHL) (BIANCA)". Protocol: CCTL019C2202. EudraCT number: 2017-005019-15. Sponsor: Novartis. 2019
  - Sub-investigator for "A Phase 1/2 Study of the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) in Subjects with Transfusion-Dependent  $\beta$  Thalassemia". Protocol: CTX001-111. EudraCT number: 2017-003351-38. Sponsor: Vertex Pharmaceuticals Incorporated. 2019
  - Sub-investigator for " A Phase I/II, open label, dose escalation study to investigate the pharmacokinetics, pharmacodynamics, safety and clinical activity of beigelomab as an initial treatment of acute Graft-versus-Host Disease in combination with standard steroid therapy". Protocol: ADN014. EudraCT number: 2017-002715-34. Sponsor: ADIENNE SA. 2019
  - Sub-investigator for "A Phase II open-label, single-arm, multi-center study of ruxolitinib added to corticosteroids in pediatric subjects with moderate and severe chronic graft vs. host disease after allogeneic stem cell transplantation". Protocol: CINC424G12201. EudraCT number: 2018-003296-35. Sponsor: Novartis. 2019
  - Sub-investigator for "A Phase I/II open-label, single-arm, multi-center study of ruxolitinib added to corticosteroids in pediatric patients with grade II-IV acute graft vs. host disease after allogeneic hematopoietic stem cell transplantation". Protocol: CINC424F12201. EudraCT number: 2018-000422-55. Sponsor: Novartis. 2019
  - Sub-investigator for "A Phase 3 Study of Lenti-D Drug Product After Myeloablative Conditioning Using Busulfan and Fludarabine in Subjects  $\leq$ 17 Years of Age With Cerebral Adrenoleukodystrophy (CALD)". Protocol: ALD-104. EudraCT number: 2018-001145-14. Sponsor: BlueBird Bio. 2019
  - Sub-investigator for "A Phase 1/2 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects With Severe Sickle Cell Disease". Protocol: CTX001-121. EudraCT number: 2018-001320-19. Sponsor: CRISPR Therapeutics. 2020
  - Sub-investigator for " A phase 1B/2, open-label, single arm, multicohort, multicenter trial to evaluate the safety and efficacy of JCAR017 in pediatric subjects with relapsed/refractory B-ALL and B-NHL". Protocol: JCAR017-BCM-004. EudraCT number: 2018-001246-34. Sponsor: Celgene Corporation. 2020
  - Sub-investigator for "An Open-label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFN $\gamma$ ) Monoclonal Antibody, and to Assess its Efficacy, Safety, Impact on Quality of Life, and Long-term Outcome in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis". Protocol: NI-0501-09. EudraCT number: 2017-003114-10. Sponsor: Novimmune S.A.. 2019

### Professional Services

- External Reviewer for KWF Kankerbestrijding (Dutch Cancer Society)
- Guest Associate Editor for Frontiers in Pediatrics: Hematology and Hematological Malignancies
- Guest Editor for Journal of Clinical Medicine

- Reviewer Editor for *Frontiers in Pediatrics: Immunology*, *Frontiers in Pediatrics: Pediatric Hematology and Hematological Malignancies*, *Frontiers in Oncology*
- Peer-reviewer for journals on pediatric hematology/oncology, immunology and general pediatrics including: *Science Translational Medicine*, *Blood*, *BMC Medicine*, *Haematologica*, *British Journal of Haematology*, *Blood Advances*, *Bone Marrow Transplantation*, *Pediatric Blood & Cancer*, *Expert Opinion on Investigational Drugs*, *Therapeutic Advances in Hematology*, *Immunology Letters*, *Journal of Pediatric Hematology/Oncology*, *Current Medical Research and Opinion*, *Pediatric Hematology and Oncology*, *Italian Journal of Pediatrics*, *World Journal of Gastroenterology*, *World Journal of Pediatrics*

### Scientific Congress Committee

- Scientific committee "International Meeting on Childhood MDS and SAA (EWOG-MDS/SAA) 2017". Rome, 28-30/09/2017

### Speaker/Chair

- GITMO educational course "Chronic GvHD Consensus Project on Criteria for Clinical Trials 2005-2015. Cosa è cambiato? Cosa cambierà?". Title: "The role of graft manipulation". Milan, 23/01/2015.
- 41th Annual Meeting EBMT. Title: "Use of zoledronic acid after TcRab/CD19-depleted haploidentical transplantation to enhance  $\gamma\delta$  T cells anti-leukemia effect ". Istanbul, 22-25/03/2015.
- 42th Annual Meeting EBMT, Presidential Symposium. Title: "Infusion of donor T cells transduced with inducible Caspase 9 (BPX-501 cells) is a safe and effective strategy to accelerate immune recovery in patients with non-malignant disorders after T cell depleted haplo-HSCT". Valencia, 3-6/04/2016.
- XLI AIEOP Annual Meeting. Title: "Approccio alle piastrinopenie nel paziente pediatrico: sfide e nuove opzioni terapeutiche". Verona, 22-24/05/2016.
- XLV AMCLI Annual Meeting. Title: "Virus: Sono utili i test quantitativi per la diagnosi e prognosi delle infezioni respiratorie?" (sessione congiunta AMCLI-GITMO-SITO: Prevenzione e diagnosi delle infezioni virali, batteriche e fungine nel paziente trapiantato). Rimini, 6-9/11/2016.
- X Meeting "Rete Ematologica Pediatrica del Piemonte e Valle d'Aosta". Keynote lecture: "Agonisti del recettore della trombopoietina (c-mpl): indicazioni in pediatria". Turin, 24/03/2017.
- 22nd European Ematology Association (EHA) Meeting. Title: "Impact of post-transplant infusion of donor T cells genetically modified with inducible Caspase 9 suicide gene (BPX-501 cells) in children with leukemia given alpha-beta T-cell depleted haplo-HSCT" Madrid, 22-25/06/2017
- Neovii Global Expert Forum – Challenges in GvHD. Title: "Prevention of acute and chronic GvHD - Approaches with cell therapies". Rome, 15/09/2017
- International Meeting on Childhood MDS and SAA (EWOG-MDS/SAA) 2017. Title: "TCRalpha/beta/CD19-cell depleted HLA-haploidentical allogeneic hematopoietic stem cell transplantation (haplo-HSCT): an effective option for childhood myelodysplastic syndromes (MDS)?" . Rome, 28-30/09/2017
- Symposium "New frontiers in cellular therapies". Title: "New haploidentical transplantation strategies in pediatric patients". Rome, 25/10/2017.
- International Symposium "Immunotherapy of childhood cancer". Title: "Blinatumomab for childhood ALL". Rome, 09-11/09/2017.
- 59th ASH Annual Meeting. Title: "Donor T Cells Genetically Modified with a Novel Suicide Gene (inducible Caspase 9, iC9) Expand and Persist over Time after Post-Allograft Infusion in Patients Given  $\alpha\beta$  T-Cell and B-Cell Depleted HLA-Haploidentical Allogeneic Stem Cell Transplantation ( $\alpha\beta$  haplo-HSCT) Contributing to Accelerate Immune Recovery". Atlanta, 9-12/12/2017.
- Amgen Spring Collegium. Title: "Update on pediatric ALL: diagnosis and treatment landscape" and "Blinatumomab for childhood ALL". Berlin, 10/04/2018.
- Invited speaker at 2nd British Society of Blood and Marrow Transplantation Scientific Day. Title: "HaploSCT with TCRab depletion and addback of iCaspase9 transduced donor T-cells". London, 02/05/2018

- 1st Cuneo City Immunotherapy Conference. Title: “ $\gamma\delta$  T cells and more in HLA-haploidentical HSCT”. Cuneo, 19/05/2018.
- XII Meeting “Rete Ematologica Pediatrica del Piemonte e Valle d'Aosta”. Keynote lecture: "Potenzialità e limiti della terapia con CAR-T". Turin, 15/02/2019.
- 1<sup>st</sup> Symposium on “Microbiota and Pediatric Hematopoietic Stem Cell Transplantation”. Title: “Fecal transplantation :update and future perspectives”. Bologna, 28/06/2019.
- Invited speaker at PASZT (Pädiatrische Arbeitsgemeinschaft für Stammzelltransplantation und Zelltherapie) Meeting 2019. Title: “How Haploidentical Stem Cell Transplantation has evolved with time”. Würzburg, 20/09/2019.
- XLIV AIEOP Annual Meeting. Title: “Studio accademico di fase I/II con cellule T esprimenti un recettore antigenico chimerico (CAR) diretto verso CD19 e il gene suicida iC9, per il trattamento della Leucemia Linfoblastica acuta (LLA-BCP) e dei Linfomi Non-Hodgkin (B-LnH) dell'età pediatrica” and “Il ruolo dell' IFN- $\gamma$  in differenti patologie pediatriche”. Catania 13-15/10/2019.
- Pediatric Allergy and Asthma Meeting 2019. Title: “Haploidentical HSCT in primary immunodeficiencies”. Florence, 17/10/2019.
- Invited speaker at SFGM-TC (Société Francophone de Greffe de Moelle et de Thérapie Cellulaire) Meeting 2019. Title:” Next generation Haplo-HSCT: changing the paradigm”. Nantes, 06/11/2019.
- Invited speaker at ALONE (Alemtuzumab alla luce dell'utilizzo clinico – aggiornamenti e nuove prospettive) 2019. Title: “What is known and unknown about HLH”. Florence, 05/12/2019.
- 61th ASH Annual Meeting. Title: “Long-term outcome of children with acute leukemia given  $\alpha\beta$  T and B-cell depleted HLA-haploidentical hematopoietic stem cell transplantation”. Orlando, 09/12/2019.
- 46th EBMT Annual Meeting. Title: “Alphabeta T and B-cell depleted HLA-haploidentical hematopoietic stem cell transplantation (TBdepl-haploHSCT) in children with non-malignant disorders”. Virtual Meeting, 29/08/2020-01/09/2020.
- XIV GITMO Meeting. Title: “Il bridging: opzioni cliniche e re-assessment dell'eleggibilità in LAL”. Virtual Meeting, 18-19/11/2020.
- 62th ASH Annual Meeting. Title: “Outcome of children with different non-malignant disorders given Alphabeta T and B-cell depleted HLA-haploidentical hematopoietic stem cell transplantation (TBdepl-haploHSCT)”. Virtual Meeting, 05-08/12/2020.

### Summary of Scientific Achievements

Product type	Number	Data Base	Start	End
Papers [international]	69	Scopus	2007	2021

Total Impact factor	352.49
Total Citations	1356 (scopus)
Average Citations per Product	19.65
Hirsch (H) index	20 (scopus)
Normalized H index*	NA

\*H index divided by the academic seniority.

## Publications

1. Locatelli F, Giorgiani G, Di-Cesare-Merlone A, **Merli P**, Sparta V, Moretta F. The changing role of stem cell transplantation in childhood. *Bone Marrow Transplant.* 2008 Jun;41 Suppl 2:S3-7
2. Baldanti F, Gatti M, Furione M, Paolucci S, Tinelli C, Comoli P, **Merli P**, Locatelli F. Kinetics of Epstein-Barr virus DNA load in different blood compartments of pediatric recipients of T-cell-depleted HLA-haploidentical stem cell transplantation. *J Clin Microbiol.* 2008 Nov;46(11):3672-7. Epub 2008 Sep 17.
3. Bernardo ME, Zecca M, Piras E, Vacca A, Giorgiani G, Cugno C, Caocci G, Comoli P, Mastronuzzi A, **Merli P**, La Nasa G, Locatelli F. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major. *Br J Haematol.* 2008 Nov;143(4):548-51.
4. Locatelli F, Testi AM, Bernardo ME, Rizzari C, Bertaina A, **Merli P**, Pession A, Giraldi E, Parasole R, Barberi W, Zecca M. Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia. *Br J Haematol.* 2009 Nov;147(3):371-8. Epub 2009 Aug 29.
5. Savasta S, **Merli P**, Ruggieri M, Bianchi L, Sparta V. Ehlers-Danlos syndrome and neurological features: a review. *Child Nerv Syst* 2011;27(3):365-71
6. Basso S, Zecca M, **Merli P**, Gurrado A, Secondino S, Quartuccio G, Guido I, Guerini P, Ottonello G, Zavras N, Maccario R, Pedrazzoli P, Comoli P. T cell therapy for nasopharyngeal carcinoma. *J Cancer.* 2011;2:341-6. Epub 2011 Jun 3.
7. Marseglia GL, **Merli P**, Caimmi D, Licari A, Labó E, Marseglia A, Ciprandi G, La Rosa M. Nasal disease and asthma. *Int J Immunopathol Pharmacol.* 2011 Oct;24(4 Suppl):7-12. Review.
8. Magni-Manzoni S, Scirè CA, Ravelli A, Klersy C, Rossi S, Muratore V, Visconti C, Lanni S, **Merli P**, Montecucco C. Ultrasound-detected synovial abnormalities are frequent in clinically inactive juvenile idiopathic arthritis, but do not predict a flare of synovitis. *Ann Rheum Dis.* 2013 Feb;72(2):223-8. doi: 10.1136/annrheumdis-2011-201264. Epub 2012 Jun 26.
9. Savasta S, **Merli P**, Introzzi F, Strocchio L, Lanati G, Incorpora G, Della Mina E, Simoncelli A, Zuffardi O, Larizza D. Agenesis of internal carotid artery and hypopituitarism: case report and review of literature. *J Clin Endocrinol Metab.* 2012 Oct;97(10):3414-20. doi: 10.1210/jc.2011-3389. Epub 2012 Jul 31. Review.
10. **Merli P**, Novara F, Montagna D, Benzo S, Tanzi M, Turin I, De Amici M, Merli A, Zuffardi O, Marseglia GL. Hyper IgE syndrome: anaphylaxis in a patient carrying the N567D STAT3 mutation. *Pediatr Allergy Immunol.* 2014 Mar 16. doi: 10.1111/pai.12217
11. Locatelli F, **Merli P**, Rutella S. At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies. *J Leukoc Biol.* 2013 Dec;94(6):1141-57
12. Locatelli F, Lucarelli B, **Merli P**. Current and future approaches to treat graft failure after allogeneic hematopoietic stem cell transplantation. *Expert Opin Pharmacother.* 2014 Jan;15(1):23-36.
13. Magni-Manzoni S, Collado P, Jousse-Joulin S, Naredo E, D'Agostino MA, Muratore V, **Merli P**, Roth J; Paediatric Ultrasound Group of the OMERACT Ultrasound Task Force. Current state of musculoskeletal ultrasound in paediatric rheumatology: results of an international survey. *Rheumatology (Oxford).* 2014 Mar;53(3):491-6.
14. Locatelli F, Moretta F, Brescia L, **Merli P**. Natural killer cells in the treatment of high-risk acute leukaemia. *Semin Immunol.* 2014;26:173-9

15. Moretta L, Montaldo E, Vacca P, Del Zotto G, Moretta F, **Merli P**, Locatelli F, Mingari MC. Human natural killer cells: origin, receptors, function, and clinical applications. *Int Arch Allergy Immunol* 2014; 164:253-64
16. Della Mina E, Ciccone R, Brustia F, Bayindir B, Limongelli I, Vetro A, Iascione M, Pezzoli L, Bellazzi R, Perotti G, De Giorgis V, Lunghi S, Coppola G, Orcesi S, **Merli P**, Savasta S, Veggiotti P, Zuffardi O. Improving molecular diagnosis in epilepsy by a dedicated high-throughput sequencing platform. *Eur J Hum Genet*. 2015 Mar;23(3):354-62. doi: 10.1038/ejhg.2014.92. Epub 2014 May 21
17. Bertaina A, **Merli P**, Rutella S, Pagliara D, Bernardo ME, Masetti R, Pende D, Falco M, Handgretinger R, Moretta F, Lucarelli B, Brescia LP, Li Pira G, Testi M, Cancrini C, Kabbara N, Carsetti R, Finocchi A, Moretta A, Moretta L, Locatelli F. HLA-haploidentical stem cell transplantation after removal of  $\alpha\beta^+$  T and B-cells in children with non-malignant disorders. *Blood* 2014;124:822-6
18. Strocchio L, Zecca M, Comoli P, Mina T, Giorgiani G, Giraldo E, Vinti L, **Merli P**, Regazzi M, Locatelli F. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease. *Br J Haematol*. 2015 Jun;169(5):726-36
19. **Merli P**, Strocchio L, Vinti L, Palumbo G, Locatelli F. Eltrombopag for treatment of thrombocytopenia-associated disorders. *Expert Opin Pharmacother*. 2015;16(14):2243-56
20. Di Nardo M, **Merli P**, Cecchetti C, Pasotti E, Bertaina A, Locatelli F. Progressive increase in D-dimer levels during extracorporeal membrane oxygenation can predict membrane oxygenator failure in children given hematopoietic stem cell transplantation? *J Crit Care*. 2016; 31(1):262-3
21. Lucarelli B, **Merli P**, Bertaina V, Locatelli F. Strategies to accelerate immune recovery after allogeneic hematopoietic stem cell transplantation. *Expert Rev Clin Immunol*. 2016;12(3):343-58. doi: 10.1586/1744666X.2016.1123091. Epub 2015 Dec 11
22. Lucarelli B, **Merli P**, Strocchio L, Cefalo MG, Brescia LP, Locatelli F. T Cell immunotherapy for immune reconstitution and GVHD prevention after allogeneic hematopoietic stem cell transplantation. *Current Stem Cell Reports* 2015; 1 (4): 206-214
23. Li Pira G, Biagini S, Cicchetti E, **Merli P**, Brescia LP, Milano GM, Montanari M. Immunoselection techniques in hematopoietic stem cell transplantation. *Transfus Apher Sci*. 2016 Jun;54(3):356-63
24. Manara E, Basso G, Zampini M, Buldini B, Tregnago C, Rondelli R, Masetti R, Bisio V, Frison M, Polato K, Cazzaniga G, Menna G, Fagioli F, **Merli P**, Biondi A, Pession A, Locatelli F, Pigazzi M. Characterization of children with FLT3-ITD acute myeloid leukemia: a report from the AIEOP AML-2002 study group. *Leukemia* 2017 Jan;31(1):18-25
25. Locatelli F, **Merli P**, Strocchio L. Transplantation for thalassemia major: alternative donors. *Curr Opin Hematol*. 2016 Nov;23(6):515-523.
26. Locatelli F, Bertaina A, Bertaina V, **Merli P**. Cytomegalovirus in hematopoietic stem cell transplant recipients - management of infection. *Expert Rev Hematol*. 2016 Nov;9(11):1093-1105
27. Bertaina A, Vinti L, Strocchio L, Gaspari S, Caruso R, Algeri M, Coletti V, Gurnari C, Romano M, Cefalo MG, Girardi K, Trevisan V, Bertaina V, **Merli P**, Locatelli F. The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood. *Br J Haematol*. 2017 Feb;176(4):629-636. doi: 10.1111/bjh.14505. Epub 2017 Jan 24
28. Buldini B, Rizzati F, Masetti R, Fagioli F, Menna G, Micalizzi C, Putti MC, Rizzari C, Santoro N, Zecca M, Disarò S, Rondelli R, **Merli P**, Pigazzi M, Pession A, Locatelli F, Basso G. Prognostic significance of flow-cytometry evaluation of minimal residual disease

- in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol. *Br J Haematol*. 2017 Apr;177(1):116-126
29. Colombini E, Guzzo I, Morolli F, Longo G, Russo C, Lombardi A, **Merli P**, Barzon L, Murer L, Piga S, Ciofi Degli Atti ML, Locatelli F, Dello Strologo L. Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients. *Pediatr Nephrol*. 2017 Aug;32(8):1433-1442. doi: 10.1007/s00467-017-3627-2. Epub 2017 Mar 9
30. Bertaina A, Zorzoli A, Petretto A, Barbarito G, Inglese E, **Merli P**, Lavarello C, Brescia LP, De Angelis B, Tripodi G, Moretta L, Locatelli F, Airoidi I. Zoledronic acid boosts  $\gamma\delta$  T-cell activity in children receiving  $\alpha\beta$  T and CD19+ cell-depleted grafts from an HLA-haplo-identical donor. *Oncoimmunology*. 2016 Sep 27;6(2):e1216291. doi: 10.1080/2162402X.2016.1216291. eCollection 2017.
31. Li Pira G, Di Cecca S, Biagini S, Girolami E, Cicchetti E, Bertaina V, Quintarelli C, Caruana I, Lucarelli B, **Merli P**, Pagliara D, Brescia LP, Bertaina A, Montanari M, Locatelli F. Preservation of Antigen-Specific Functions of  $\alpha\beta$  T Cells and B Cells Removed from Hematopoietic Stem Cell Transplants Suggests Their Use As an Alternative Cell Source for Advanced Manipulation and Adoptive Immunotherapy. *Front Immunol*. 2017 Mar 23;8:332. doi: 10.3389/fimmu.2017.00332. eCollection 2017.
32. Stabile H, Nisti P, Peruzzi G, Fionda C, Pagliara D, Brescia PL, **Merli P**, Locatelli F, Santoni A, Gismondi A. Reconstitution of multifunctional CD56lowCD16low natural killer cell subset in children with acute leukemia given  $\alpha/\beta$  T cell-depleted HLA-haploidentical haematopoietic stem cell transplantation. *Oncoimmunology*. 2017 Aug 10;6(9):e1342024. doi: 10.1080/2162402X.2017.1342024. eCollection 2017
33. Locatelli F, **Merli P**, Pagliara D, Li Pira G, Falco M, Pende D, Rondelli R, Lucarelli B, Brescia LP, Masetti R, Milano GM, Bertaina V, Algeri M, Pinto RM, Strocchio L, Meazza R, Grapulin L, Handgretinger R, Moretta A, Bertaina A, Moretta L. Outcome of children with acute leukemia given HLA-haploidentical HSCT after  $\alpha\beta$  T-cell and B-cell depletion. *Blood*. 2017 Aug 3;130(5):677-685. doi: 10.1182/blood-2017-04-779769. Epub 2017 Jun 6
34. Locatelli F, Bernardo ME, Bertaina A, Rognoni C, Comoli P, Rovelli A, Pession A, Fagioli F, Favre C, Lanino E, Giorgiani G, **Merli P**, Pagliara D, Prete A, Zecca M. Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol*. 2017 Aug;18(8):1126-1136
35. Starc N, Ingo D, Conforti A, Rossella V, Tomao L, Pitisci A, De Mattia F, Brigida I, Algeri M, Montanari M, Palumbo G, **Merli P**, Rossi P, Aiuti A, Locatelli F, Bernardo ME. Biological and functional characterization of bone marrow-derived mesenchymal stromal cells from patients affected by primary immunodeficiency. *Sci Rep*. 2017 Aug 15;7(1):8153. doi: 10.1038/s41598-017-08550-5.
36. Locatelli F, **Merli P**, Bertaina A. Rabbit anti-human T-lymphocyte globulin and hematopoietic transplantation. *Oncotarget*. 2017 Sep 14;8(57):96460-96461.
37. Locatelli F, Algeri M, **Merli P**, Strocchio L. Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia. *Expert Rev Hematol*. 2018 Feb;11(2):129-143.
38. Messina C, Zecca M, Fagioli F, Rovelli A, Giardino S, **Merli P**, Porta F, Aricò M, Sieni E, Basso G, Ripaldi M, Favre C, Pillon M, Marzollo A, Rabusin M, Cesaro S, Algeri M, Caniglia M, Di Bartolomeo P, Ziino O, Saglio F, Prete A, Locatelli F. Outcomes of Children with Hemophagocytic Lymphohistiocytosis Given Allogeneic Hematopoietic Stem Cell Transplantation in Italy. *Biol Blood Marrow Transplant*. 2018 Jun;24(6):1223-1231. doi: 10.1016/j.bbmt.2018.01.022. Epub 2018 Feb 2.

39. Del Bufalo F, **Merli P**, Alessi I, Locatelli F. B-cell depleting immunotherapies: therapeutic opportunities and toxicities. *Expert Rev Clin Immunol*. 2019 May;15(5):497-509. doi: 10.1080/1744666X.2019.1573672. Epub 2019 Feb 6
40. **Merli P**, Caruana I, De Vito R, Strocchio L, Weber G, Del Bufalo F, Buatois V, Montanari P, Cefalo MG, Pitisci A, Algeri M, Galaverna F, Quintarelli C, Cirillo V, Pagliara D, Ferlin W, Ballabio M, De Min C, Locatelli F. Role of IFN $\gamma$  in immune-mediated graft failure occurring after allogeneic hematopoietic stem cell transplantation. *Haematologica*. 2019 Nov;104(11):2314-2323. doi: 10.3324/haematol.2019.216101. Epub 2019 Feb 21
41. **Merli P**, Algeri M, Del Bufalo F, Locatelli F. Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia. *Curr Hematol Malig Rep*. 2019 Apr;14(2):94-105. doi: 10.1007/s11899-019-00502-2.
42. Biagi E, Zama D, Rampelli S, Turroni S, Brigidi P, Consolandi C, Severgnini M, Picotti E, Gasperini P, **Merli P**, Decembrino N, Zecca M, Cesaro S, Faraci M, Prete A, Locatelli F, Pession A, Candela M, Masetti R. Early gut microbiota signature of aGvHD in children given allogeneic hematopoietic cell transplantation for hematological disorders. *BMC Med Genomics*. 2019 Mar 7;12(1):49. doi: 10.1186/s12920-019-0494-7.
43. Colafati GS, Voicu IP, Carducci C, Caulo M, Vinci M, Diomedei-Camassei F, **Merli P**, Carai A, Miele E, Cacchione A, Tomà P, Locatelli F, Mastronuzzi A. Direct Involvement of Cranial Nerve V at Diagnosis in Patients With Diffuse Intrinsic Pontine Glioma: A Potential Magnetic Resonance Predictor of Short-Term Survival. *Front Oncol*. 2019 Apr 4;9:204. doi: 10.3389/fonc.2019.00204. eCollection 2019.
44. Cifaldi C, Brigida I, Barzaghi F, Zoccolillo M, Ferradini V, Petricone D, Cicalese MP, Lazarevic D, Cittaro D, Omrani M, Attardi E, Conti F, Scarselli A, Chiriaco M, Di Cesare S, Licciardi F, Davide M, Ferrua F, Canessa C, Pignata C, Giliani S, Ferrari S, Fousteri G, Barera G, **Merli P**, Palma P, Cesaro S, Gattorno M, Trizzino A, Moschese V, Chini L, Villa A, Azzari C, Finocchi A, Locatelli F, Rossi P, Sangiuolo F, Aiuti A, Cancrini C, Di Matteo G. Targeted NGS Platforms for Genetic Screening and Gene Discovery in Primary Immunodeficiencies. *Front Immunol*. 2019 Apr 11;10:316. doi: 10.3389/fimmu.2019.00316. eCollection 2019.
45. Ceglie G, Papetti L, Figà Talamanca L, Lucarelli B, Algeri M, Gaspari S, Li Pira G, Colafati GS, Montanari M, Valeriani M, Locatelli F, **Merli P**. T-cell depleted HLA-haploidentical HSCT in a child with neuromyelitis optica. *Ann Clin Transl Neurol*. 2019 Oct;6(10):2110-2113.
46. Tumino N, Besi F, Di Pace AL, Mariotti FR, **Merli P**, Li Pira G, Galaverna F, Pitisci A, Ingegnere T, Pelosi A, Quatrini L, Munari E, Locatelli F, Moretta L, Vacca P. PMN-MDSC are a new target to rescue graft-versus-leukemia activity of NK cells in haplo-HSC transplantation. *Leukemia*. 2020 Mar;34(3):932-937. doi: 10.1038/s41375-019-0585-7. Epub 2019 Oct 4.
47. Lam MT, Coppola S, Krumbach OHF, Prencipe G, Insalaco A, Cifaldi C, Brigida I, Zara E, Scala S, Di Cesare S, Martinelli S, Di Rocco M, Pascarella A, Niceta M, Pantaleoni F, Ciolfi A, Netter P, Carisey AF, Diehl M, Akbarzadeh M, Conti F, **Merli P**, Pastore A, Levi Mortera S, Camerini S, Farina L, Buchholzer M, Pannone L, Cao TN, Coban-Akdemir ZH, Jhangiani SN, Muzny DM, Gibbs RA, Basso-Ricci L, Chiriaco M, Dvorsky R, Putignani L, Carsetti R, Janning P, Stray-Pedersen A, Erichsen HC, Horne A, Bryceson YT, Torralba-Raga L, Ramme K, Rosti V, Bracaglia C, Messia V, Palma P, Finocchi A, Locatelli F, Chinn IK, Lupski JR, Mace EM, Cancrini C, Aiuti A, Ahmadian MR, Orange JS, De Benedetti F, Tartaglia M. A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function. *J Exp Med*. 2019 Dec 2;216(12):2778-2799. doi: 10.1084/jem.20190147. Epub 2019 Oct 10


48. Zangari P, Cifaldi C, Di Cesare S, Di Matteo G, Chiriaco M, Amodio D, Cotugno N, De Luca M, Surace C, Ladogana S, Gardini S, **Merli P**, Algeri M, Rossi P, Palma P, Cancrini C, Finocchi A. Novel Compound Heterozygous Mutations in IL-7 Receptor  $\alpha$  Gene in a 15-Month-Old Girl Presenting With Thrombocytopenia, Normal T Cell Count and Maternal Engraftment. *Front Immunol.* 2019 Oct 30;10:2471. doi: 10.3389/fimmu.2019.02471. eCollection 2019.
49. Srinagesh HK, Özbek U, Kapoor U, Ayuk F, Aziz M, Ben-David K, Choe HK, DeFilipp Z, Etra A, Grupp SA, Hartwell MJ, Hexner EO, Hogan WJ, Karol AB, Kasikis S, Kitko CL, Kowalyk S, Lin JY, Major-Monfried H, Mielke S, **Merli P**, Morales G, Ordemann R, Pulsipher MA, Qayed M, Reddy P, Reshef R, Rösler W, Sandhu KS, Schechter T, Shah J, Sigel K, Weber D, Wölfl M, Wudhikarn K, Young R, Levine JE, Ferrara JLM. The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. *Blood Adv.* 2019 Dec 10;3(23):4034-4042.
50. Aziz MD, Shah J, Kapoor U, Dimopoulos C, Anand S, Augustine A, Ayuk F, Chaudhry M, Chen YB, Choe HK, Etra A, Gergoudis S, Hartwell MJ, Hexner EO, Hogan WJ, Kitko CL, Kowalyk S, Kröger N, **Merli P**, Morales G, Nakamura R, Ordemann R, Pulsipher MA, Qayed M, Reshef R, Rösler W, Schechter T, Schreiner E, Srinagesh H, Wölfl M, Wudhikarn K, Yanik G, Young R, Özbek U, Ferrara JLM, Levine JE. Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant. *Leukemia.* 2020 Feb 4. doi: 10.1038/s41375-020-0726-z. [Epub ahead of print]
51. **Merli P**, Putignani L, Ruggeri A, Del Chierico F, Gargiullo L, Galaverna F, Gaspari S, Pagliara D, Russo A, Pane S, Strocchio L, Algeri M, Rea F, Romeo EF, Bernaschi P, Onetti Muda A, Dallapiccola B, Locatelli F. Decolonization of multi-drug resistant bacteria by fecal microbiota transplantation in five pediatric patients before allogeneic hematopoietic stem cell transplantation: gut microbiota profiling, infectious and clinical outcomes. *Haematologica.* 2020 Nov 1;105(11):2686-2690. doi: 10.3324/haematol.2019.244210.
52. Bottari G, **Merli P**, Guzzo I, Stoppa F, Ruggeri A, Di Nardo M, Del Bufalo F, Galaverna F, Cecchetti C, Locatelli F. Multimodal Therapeutic Approach of Cytokine Release Syndrome Developing in a Child Given Chimeric Antigen Receptor-Modified T Cell Infusion. *Crit Care Explor.* 2020 Jan 29;2(1):e0071. doi: 10.1097/CCE.0000000000000071. eCollection 2020 Jan.
53. **Merli P**, Vacca P, Galaverna F, Tumino N, Moretta L, Locatelli F. TCR $\alpha\beta$ /CD19 depleted hematopoietic stem cell transplantation from haploidentical donors: dissecting the GvL/GvHD conundrum. *Bone Marrow Transplant.* Jul;55(7):1483-1484. doi: 10.1038/s41409-020-0891-8. Epub 2020 Apr 14. doi: 10.1038/s41409-020-0891-8.
54. Guercio M, Orlando D, Di Cecca S, Sinibaldi M, Boffa I, Caruso S, Abbaszadeh Z, Camera A, Cembrola B, Bovetti K, Manni S, Caruana I, Ciccone R, Del Bufalo F, **Merli P**, Vinti L, Girardi K, Ruggeri A, De Stefanis C, Pezzullo M, Giorda E, Scarsella M, De Vito R, Barresi S, Ciolfi A, Tartaglia M, Moretta L, Locatelli F, Quintarelli C, De Angelis B. CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells. *Haematologica.* 2020 May 7;haematol.2019.231183. doi: 10.3324/haematol.2019.231183. Online ahead of print.
55. **Merli P**, Algeri M, Galaverna F, Milano GM, Bertaina V, Biagini S, Girolami E, Palumbo G, Sinibaldi M, Becilli M, Leone G, Boccieri E, Grapulin L, Gaspari S, Airoidi I, Strocchio L, Pagliara D, Locatelli F. Immune Modulation Properties of Zoledronic Acid on TcR $\gamma\delta$  T-Lymphocytes After TcR $\alpha\beta$ /CD19-Depleted Haploidentical Stem Cell Transplantation: An analysis on 46 Pediatric Patients Affected by Acute Leukemia. *Front Immunol.* 2020 May 12;11:699. doi: 10.3389/fimmu.2020.00699. eCollection 2020.
56. Cammarata-Scalisi F, Girardi K, Strocchio L, **Merli P**, Bernardin AG, Galeotti A, Magliarditi F, Inserra A, Callea M. Oral Manifestations and Complications in Childhood

- Acute Myeloid Leukemia. *Cancers (Basel)*. 2020 Jun 19;12(6):E1634. doi: 10.3390/cancers12061634.
57. **Merli P**, Gentile L, Quagliarella F, Cefalo MG, Strocchio L, Locatelli F, Russo C, Gaspari S. QuantiFERON-TB Gold can help clinicians in the diagnosis of haemophagocytic lymphohistiocytosis. *Br J Haematol*. 2020 Jul 26. doi: 10.1111/bjh.17001. Online ahead of print.
58. Ceglie G, Papetti L, Valeriani M, **Merli P**. Hematopoietic Stem Cell Transplantation in Neuromyelitis Optica-Spectrum Disorders (NMO-SD): State-of-the-Art and Future Perspectives. *Int J Mol Sci*. 2020 Jul 26;21(15):E5304. doi: 10.3390/ijms21155304.
59. Meazza R, Falco M, Loiacono F, Canevali P, Della Chiesa M, Bertaina A, Pagliara D, **Merli P**, Indio V, Galaverna F, Algeri M, Moretta F, Colomar-Carando N, Muccio L, Sivori S, Pession A, Mingari MC, Moretta L, Moretta A, Locatelli F, Pende D. Phenotypic and Functional Characterization of NK Cells in  $\alpha\beta$ T-Cell and B-Cell Depleted Haplo-HSCT to Cure Pediatric Patients with Acute Leukemia. *Cancers (Basel)*. 2020 Aug 5;12(8):2187. doi: 10.3390/cancers12082187.
60. Cefalo MG, Ronco F, Di Felice G, Rinelli M, Oriana V, Massoud M, **Merli P**, Luciani M. Effectiveness of emicizumab in preventing life-threatening bleeding complications in type 3 von Willebrand disease with inhibitors: A paediatric report. *Haemophilia*. 2020 Nov 20. doi: 10.1111/hae.14209. Epub ahead of print. PMID: 33216432.
61. Gergoudis SC, DeFilipp Z, Özbek U, Sandhu KS, Etra AM, Choe HK, Kitko CL, Ayuk F, Aziz M, Baez J, Ben-David K, Bunworasate U, Gandhi I, Hexner EO, Hogan WJ, Holler E, Kasikis S, Kowalyk SM, Lin JY, **Merli P**, Morales G, Nakamura R, Reshef R, Rösler W, Srinagesh H, Young R, Chen YB, Ferrara JLM, Levine JE. Biomarker-guided preemption of steroid-refractory graft-versus-host disease with  $\alpha$ -1-antitrypsin. *Blood Adv*. 2020 Dec 22;4(24):6098-6105. doi: 10.1182/bloodadvances.2020003336. PMID: 33351103; PMCID: PMC7756981.
62. **Merli P**, Jordan MB, Locatelli F. Possible roads to improve hemophagocytic lymphohistiocytosis outcome. *Blood Adv*. 2020 Dec 22;4(24):6127-6129. doi: 10.1182/bloodadvances.2020003263. PMID: 33351106; PMCID: PMC7756988.
63. Di Paola A, Palumbo G, **Merli P**, Argenziano M, Tortora C, Strocchio L, Roberti D, Santoro C, Perrotta S, Rossi F. Effects of Eltrombopag on In Vitro Macrophage Polarization in Pediatric Immune Thrombocytopenia. *Int J Mol Sci*. 2020 Dec 24;22(1):E97. doi: 10.3390/ijms22010097. PMID: 33374151.
64. **Merli P**, Algeri M, Gaspari S, Locatelli F. Novel Therapeutic Approaches to Familial HLH (Emapalumab in FHL). *Front. Immunol*. 2020. <https://doi.org/10.3389/fimmu.2020.608492>
65. **Merli P**, Quintarelli C, Strocchio L, Locatelli F. The role of interferon-gamma and its signaling pathway in pediatric hematological disorders. *Pediatr Blood Cancer*. 2021 Jan 23:e28900. doi: 10.1002/pbc.28900. Epub ahead of print. PMID: 33484058.
66. Weber G, Strocchio L, Del Bufalo F, Algeri M, Pagliara D, Arnone CM, De Angelis B, Quintarelli C, Locatelli F, **Merli P\***, Caruana I\*. Identification of New Soluble Factors Correlated With the Development of Graft Failure After Haploidentical Hematopoietic Stem Cell Transplantation. *Front. Immunol.*, 29 January 2021 | <https://doi.org/10.3389/fimmu.2020.613644>
67. Bakhtiar S, Salzmann-Manrique E, Blok HJ, Eikema DJ, Hazelaar S, Ayas M, Toren A, Goldstein G, Moshous D, Locatelli F, **Merli P**, Michel G, Öztürk G, Schulz A, Heilmann C, Ifversen M, Wynn RF, Aleinikova O, Bertrand Y, Tbakhi A, Veys P, Karakukcu M, Kupesiz A, Ghavamzadeh A, Handgretinger R, Unal E, Perez-Martinez A, Gokce M, Porta F, Aksu T, Karasu G, Badell I, Ljungman P, Skorobogatova E, Yesilipek A, Zuckerman T, Bredius RGG, Stepensky P, Shadur B, Slatter M, Gennery AR, Albert MH, Bader P, Lankester A on behalf of the Pediatric Diseases Working Party and the Inborn Errors

Working Party of EBMT. Allogeneic hematopoietic stem cell transplantation in leukocyte adhesion deficiency type I and III. Blood Adv (2021) 5 (1): 262–273.  
<https://doi.org/10.1182/bloodadvances.2020002185>

Luogo e data Roma, 10/02/2021

Firma .....

A handwritten signature in black ink, consisting of several loops and a long horizontal stroke, is written over a dotted line.

